Overview

Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer

Status:
Completed
Trial end date:
2002-09-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of chloroquinoxaline sulfonamide in treating patients who have small cell lung cancer that has not responded to platinum-based chemotherapy.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
City of Hope Medical Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Sulfanilamides
Criteria
DISEASE CHARACTERISTICS: Histologically confirmed platinum-refractory small cell lung
cancer No response or progression during or within 6 months of completing platinum based
therapy Measurable disease No symptomatic brain or leptomeningeal metastases

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy: At
least 12 weeks Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least
100,000/mm3 No hemolytic anemia Hepatic: Bilirubin normal AST no greater than 2.5 times
upper limit of normal Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance
at least 60 mL/min Cardiovascular: No history of cardiac arrhythmias Other: No other active
malignancy requiring concurrent treatment No allergy to sulfonamides Not pregnant or
nursing Negative pregnancy test Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
Characteristics No more than 2 prior chemotherapy regimens At least 3 weeks since prior
chemotherapy and recovered Endocrine therapy: No concurrent corticosteroids to control
symptoms of brain and/or leptomeningeal metastases Radiotherapy: At least 4 weeks since
prior radiotherapy No concurrent radiotherapy to measurable lesions Surgery: Not specified
Other: No concurrent hypoglycemic agents (including insulin)